Abstract
Schizophrenia is a burdensome disease requiring consistent long-term treatment. Antipsychotic medication switching is common and nonadherence to oral antipsychotics is reported in up to two-thirds of patients with schizophrenia. Lumateperone is a mechanistically novel antipsychotic that was initially FDA-approved in December 2019 to treat adults with schizophrenia. In December 2021, lumateperone was approved to treat depressive episodes associated with bipolar I or bipolar II disorder, as monotherapy and as adjunctive therapy with lithium or valproate. This analysis evaluated real-world persistency of lumateperone 42 mg to treat schizophrenia using open claims databases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
